What happened with ARDX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Ardelyx, Inc. sells two prescription medicines containing tenapanor, a drug it discovered and developed. IBSRELA treats adults with irritable bowel syndrome with constipation and accounts for most revenue. XPHOZAH lowers blood phosphorus in adults with chronic kidney disease on dialysis; its approval limits it to add-on treatment for patients whose phosphate binders do not work adequately or who cannot tolerate them.
Wholesalers and specialty pharmacies buy the medicines from Ardelyx for distribution to patients. BioRidge Pharma is its largest product-sales customer, accounting for a large share of gross sales. Government and private insurance coverage substantially affects whether patients can obtain the drugs and how much Ardelyx earns. A smaller business supplies tenapanor to overseas commercialization partners and earns licensing payments; Kyowa Kirin is the main customer for that supply business.
XPHOZAH is now included in Medicare’s bundled payment for dialysis services rather than covered separately under Part D, a change that materially reduced its revenue. Ardelyx also relies entirely on outside manufacturers, with some manufacturing stages dependent on a single supplier and no qualified alternative. It may promote IBSRELA and XPHOZAH only for their FDA-approved uses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Ardelyx depends chiefly on IBSRELA uptake and XPHOZAH reimbursement, while its Japanese tenapanor partner Kyowa Kirin also contributes product-supply revenue.
Akebia sells Auryxia to control phosphorus in the same adult dialysis population served by Ardelyx’s XPHOZAH, tying both businesses to Medicare’s bundled dialysis payments. Their interests can diverge: Akebia says a successful Ardelyx challenge removing oral-only phosphorus-lowering drugs from the bundle could reduce anticipated Auryxia revenue.
Unicycive’s OLC could add competition in phosphorus control for the dialysis patients treated by Ardelyx’s XPHOZAH, but it remains a phosphate-binding drug in development. Watch its approval and Medicare payment decisions: a possible first-half 2027 launch depends on approval, and separate reimbursement requires a transitional add-on payment award.
Fresenius Medical Care connects Ardelyx to both competing phosphorus-control drugs and the clinics paid to care for dialysis patients: it sells phosphate binders and operates clinics affected by the payment bundle that now includes XPHOZAH. Its dialysis-clinic business is the part to watch for the provider economics behind that reimbursement change.
DaVita exposes Ardelyx investors to the care-provider side of XPHOZAH reimbursement: it provides dialysis to the patient population eligible for the drug, which now falls within Medicare’s bundled dialysis payment. Watch DaVita’s U.S. dialysis business for how that payment framework affects providers, rather than as a competing drug business.
DaVita Inc. earningsDVA
DaVita's U.S. dialysis business will show how the Medicare bundled payment affects providers, offering context for the reimbursement setting around Ardelyx's XPHOZAH.
Read DaVita's U.S. dialysis revenue and operating performance for signs of whether providers can absorb care costs under the bundled payment. Steady results would suggest the payment framework may be manageable for providers, but would not prove XPHOZAH demand or coverage has recovered; weaker results would point to pressure on clinics in the same payment system.
Ardelyx, Inc. earningsThis company
Ardelyx sells IBSRELA and XPHOZAH, and this report will show whether IBSRELA's growth can offset the pressure on XPHOZAH after it lost Medicare Part D coverage.
Read product sales for IBSRELA and XPHOZAH separately. Continued IBSRELA growth with XPHOZAH stabilizing would show the first drug is offsetting some of the damage from the Medicare coverage change. If IBSRELA growth slows while XPHOZAH remains weak, Ardelyx's sales remain more exposed to the loss of Part D coverage.
